Making trials faster
& more successful

The automation engine for admin-free clinical trials

Research Grid (R.grid) has developed two industry-leading products leveraging its AI-powered automation engine. Together, Inclusive and TrialEngine form the only end-to-end platform to automate the back office of clinical trials, from pre-trial to trial close. Both are designed to tackle trial management bottlenecks and automate manual processes, supporting our mission of making clinical trials faster and more successful.
Our smart software cuts months of your trial timeline by connecting every trial stage in one place and automating complex manual workflows using AI

Faster and more successful

We make patient recruitment and engagement easy while drastically reducing administrative errors to give every trial the best chance of success

About Inclusive

Inclusive is a smart patient, community engagement sourcing and management platform for use in the early trial preparation phase.

It has created the largest patient network in the world, providing access to more than 300 million patients across more than 90,000 communities.

Using smart automations, it makes it quick and easy to find and communicate with stakeholders and participants from diverse communities to avoid the delays and failures caused by weak or unrepresentative recruitment.

Critically, it also facilitates and promotes patient engagement, which is another critical factor to give trials the best chance of success.

About TrialEngine

TrialEngine is a smart clinical trial automation system (CTAS) that handles the administration, data, and reporting workflows during the trial and post-trial.

It leverages custom AI algorithms and process automation to complete tasks such as protocol development, study documents and data extraction in a matter of minutes.

This contrasts sharply with legacy clinical trial management systems (CTMS) where these tasks can take months or even years. The extremely manual workflows and operations with existing CTMS systems, makes them a major source of bottlenecks and expensive delays.

Supporting world-leading trials

Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image
Image